Abstract: Provided herein is a pharmaceutical composition comprising cytisine and a nitrite scavenger, wherein, upon storage of the composition at about 60° C., the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng/mg or less after about 30 days. A method of manufacturing a cytisine tablet is also provided.

Abstract: Provided herein is a cytisine formulation comprising cytisine, a nitrite scavenger, a glidant, a lubricant, a buffering agent and one or more fillers, wherein, upon storage of the composition at about 60° C., the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng/mg or less after about 30 days.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4] oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: A system operable to analyze applicant features having at least one user computing device in operable communication with a user network. An application server in operable communication with the user network to host an application system for analyzing the plurality of applicant features and transmitting the plurality of applicant features to a comparator operable to compare the plurality of features to one or more other applicants.

Abstract: A system operable to analyze applicant features having at least one user computing device in operable communication with a user network. An application server in operable communication with the user network to host an application system for analyzing the plurality of applicant features and transmitting the plurality of applicant features to a comparator operable to compare the plurality of features to one or more other applicants.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: A hand-held test meter for use with an electro-chemical-based analytical test strip in the determination of an analyte in a bodily fluid sample includes a housing; a strip port connector disposed at least partially within the housing and configured to receive an electro-chemical based analytical test strip; a micro-controller disposed in the housing and configured to generate a micro-controller command signal; an electrode bias drive circuit block disposed in the housing and configured to generate a bias drive signal based on the micro-controller command signal, and a dynamic bias drive adjustment circuit block disposed in the housing and configured to receive at least one sensed electrode voltage and to adjust a bias drive signal from the electrode bias drive circuit block based on the sensed electrode voltage to create an adjusted bias drive signal.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis (trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: A test meter and related method for monitoring the condition of a backlight battery of the meter in which the meter includes a housing, controller, display with backlight and a battery monitoring circuit. An off-time of the meter is measured and compared to a predetermined recovery time of the backlight battery. If the off-time of the meter is greater than the predetermined recovery time of the backlight battery, a voltage of the backlight battery is measured at a predetermined time after energizing the backlight and compared to a first predetermined voltage in excess of a threshold voltage of the backlight battery. If the measured voltage is less than the first predetermined voltage, the measured voltage is compared to a second predetermined voltage between the first predetermined voltage and the threshold voltage. A battery depletion warning is displayed if the measured voltage is less than the second predetermined voltage.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Abstract: A hand-held test meter for use with an electro-chemical-based analytical test strip in the determination of an analyte in a bodily fluid sample includes a housing; a strip port connector disposed at least partially within the housing and configured to receive an electro-chemical based analytical test strip; a micro-controller disposed in the housing and configured to generate a micro-controller command signal; an electrode bias drive circuit block disposed in the housing and configured to generate a bias drive signal based on the micro-controller command signal, and a dynamic bias drive adjustment circuit block disposed in the housing and configured to receive at least one sensed electrode voltage and to adjust a bias drive signal from the electrode bias drive circuit block based on the sensed electrode voltage to create an adjusted bias drive signal.

Abstract: A physiological measurement system includes a biosensor providing a signal for a fluid sample. A processor determines a physiological parameter in the form of an analyte concentration using the signal from the biosensor. A network interface conveys data between the processor and a social network. The processor can transmit a query for analyte-data-request records to the social network, receive an indication of an analyte-data-request record from the social network, and transmit the determined analyte data or physiologic data to the social network in response to the indication. The processor can alternatively retrieve user credentials from a storage device, transmit the credentials and the analyte data to the social network, retrieve from the social network different-user response data corresponding to the transmission, and present an indication of the response data. Methods for processing analyte or physiologic data are also described.

Abstract: A test meter and related method for monitoring the condition of a backlight battery of the meter in which the meter includes a housing, controller, display with backlight and a battery monitoring circuit. An off-time of the meter is measured and compared to a predetermined recovery time of the backlight battery. If the off-time of the meter is greater than the predetermined recovery time of the backlight battery, a voltage of the backlight battery is measured at a predetermined time after energizing the backlight and compared to a first predetermined voltage in excess of a threshold voltage of the backlight battery. If the measured voltage is less than the first predetermined voltage, the measured voltage is compared to a second predetermined voltage between the first predetermined voltage and the threshold voltage. A battery depletion warning is displayed if the measured voltage is less than the second predetermined voltage.

Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.